Counterfeit Medicines in Africa

Counterfeit medicines remain a serious public health challenge in many parts of Africa. These falsified products may contain incorrect ingredients, the wrong dosage, or no active substance at all, placing patients at significant risk and undermining the safe treatment of disease.

Beyond the direct impact on individual health, counterfeit medicines also weaken trust in healthcare systems and make it more difficult for healthcare providers to deliver effective and reliable care. The issue highlights the importance of quality assurance, secure supply chains and access to safe, properly regulated medicines.

This video provides additional context on the risks associated with counterfeit medicines and the broader public health consequences in affected regions.

Reducing the circulation of falsified medicines is not only a regulatory priority, but also a humanitarian and healthcare imperative. Sustainable improvement depends on stronger oversight, reliable sourcing, better traceability and continued collaboration between local authorities, healthcare institutions and international partners.

At Orelia Pharma, these challenges underline the importance of responsible pharmaceutical distribution and the broader need to support access to safe, high-quality medicines in regions where patients remain especially vulnerable to supply chain weaknesses and substandard products.